Prevention of Syncope Trial - POST
The goal of the trial is to evaluate treatment with the beta-blocker metoprolol for the prevention of vasovagal syncope.
Beta-blocker therapy with metoprolol will increase the time to the first recurrence of syncope compared with placebo.
Patients Enrolled: 220
Mean Follow Up: 1 year
Positive tilt test with 3 syncopal spells preceding the tilt test
Seizures or other causes of syncope; important heart disease; a contraindication to or need for beta blockers; a permanent pacemaker; a major noncardiovascular disease; or previous use of beta blockers at a dose greater than the equivalent of metoprolol 25mg twice daily for the purpose of suppressing vasovagal syncope.
Time to first syncope recurrence
Syncope frequency, presyncope, and quality of life
Patients will be randomized 1:1 to receive metoprolol or placebo, and followed for 1 year.
Not yet reported
Sheldon R, et al. Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope; rationale and study design. Europace. 2003 Jan;5(1):71-5
Keywords: Recurrence, Syncope, Vasovagal, Tilt-Table Test, Metoprolol
< Back to Listings